FDA to Expand Review of Chemical Preservatives Used in Food
By
The Food and Drug Administration is planning to expand its review of food additives beyond artificial dyes, targeting preservatives and chemicals used as whitening agents and dough conditioners.
The agency will issue an updated list of chemicals that it will evaluate, including the common preservatives butylated hydroxytoluene, or BHT, and butylated hydroxyanisol, or BHA. Azodicarbonamide, or ADA, a whitening agent used in cereal flour and as a dough conditioner, will also be on the list, the agency said in a statement.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Breyers Ice Creams Recalled After Flavor Containing Life-Threatening Allergen Was Packaged as Another Flavor
6,668 cases of Breyers Chocolate Truffle Ice Cream across the United States have been recalled by Unilever Manufacturing The affected ice cream cartons actually contain Rocky Road Ice Cream, which contains almonds, a potentially "life-threatening" allergen The U.S. Food and Drug Administration announced the recall on June 10Over 6,600 cases of Breyers Ice Cream have been recalled amid concerns that the product is mislabeled and contains a "life-threatening" allergen. The U.S. Food and Drug Administration confirmed that 6,668 cases of Breyers Chocolate Truffle Ice Cream were voluntarily recalled by Unilever Manufacturing on June 2 in a Tuesday, June 10 statement. The cause for the recall was determined to be "undeclared allergens and mislabeled product." "Rocky Road Ice was packaged with Chocolate Truffle Ice Cream labeled tub and a Rocky Road Ice Cream lid. Tub said 'may contain tree nuts' the lid said it did contain almonds," the FDA clarified about the recall. is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! The FDA declared this a Class II recall, which is defined as "a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." A representative for Breyers commented on the recall in a statement shared with PEOPLE, saying, "Unilever in the U.S. is voluntarily recalling one lot of Breyers Chocolate Truffle 1.5 quart tubs after some were found to contain Rocky Road ice cream, which includes almonds not listed on the label." The statement continued: "People with an almond allergy should not consume the product due to risk of serious or life-threatening allergic reaction. The safety and quality of our products is our top priority. For more information, consumers can visit or call 1-800-931-2826." It is unclear where exactly the cases of ice cream were distributed across the United States. The FDA reported the distribution as targeting "distribution centers and retail locations across the U.S." Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Rocky Road is a flavor of ice cream that contains almonds. Although almonds are considered tree nuts, the label for Breyers Chocolate Truffle Ice Cream only says that the product "may contain tree nuts." The Breyers recall comes a few weeks after nearly 18,000 containers of Wells Dairy ice cream and frozen yogurt were recalled due to contamination with hard plastics. Wells Enterprises, which produces Wells Dairy products, was responsible for the recall, which targeted 22 different flavors of frozen desserts. Read the original article on People
WebMD
an hour ago
- WebMD
More Thoughts on the Myth of the Perfect Patient
In my last post, I talked about the extreme efforts I took to be the healthiest, most perfect MS patient. I realized I had more to say on the subject. If the average person looked at my diet today, they'd still think I was pretty strict. I still cut out most inflammatory foods: gluten, dairy, excessive sugar, corn, oats, veggie oils, and highly processed foods. But some "bad" habits have definitely snuck back into my life. I drink coffee every day, have Diet Coke a few times a week, indulge in (gluten-free and vegan) sugary desserts, eat out often, sacrifice sleep for fun, no longer read food labels with a magnifying glass, blast music through my headphones, and occasionally grab fast food after a night out. And with these choices comes guilt. Constant, nagging guilt that I indulge so much despite having an inflammatory condition. You would think I'd have more self-restraint, given the implications, and yet I've entered a chapter in my life where that's just … not a priority. People are often surprised by my lifestyle. Those who knew me throughout my MS journey saw me transform from a lifestyle that was average, to extremely strict and healthy, to average again, and now possibly even slightly unhealthy. They're shocked that I've "regressed" so much, and I get questioned about it constantly. I'm always uncomfortable answering. What do I say? "Yes, I still have multiple sclerosis and it's a really scary disease, but I'm just kind of taking a break from being healthy"? Or when people who newly meet me realize I have MS, they often question how it's possible when we seemingly live the same lives. They applaud me for having so much energy and "handling it so well." But they don't see me take three-hour naps just to get through my day. They don't see the migraines, numbness, and spasms that creep up on me. They don't see the constant doctor appointments, blood tests, and MRIs. Why are they so shocked by my diagnosis? Why are people shocked that I stopped eating such a strict diet? Why do they make comments about it? Why do their comments make me feel even more guilty? Why are they allowed to drink a can of soda, but not me? Nothing is worse than when someone points out I'm doing something unhealthy and asks how it affects my MS. Even when they don't mention my MS directly, the implications of my chronic illness hang heavy in the air. Because the reality is they're projecting an image of a perfect patient onto me, and that simply does not exist. Even when I was at my healthiest, I wasn't perfect. Eating that healthy gave me extreme anxiety, and any misstep sent me into a spiral. But truly, you cannot win with a chronic illness. When you try to eat super healthy, you put immense pressure and stress on yourself. When you decide not to prioritize it, the guilt and shame eat at you. Not to mention that your body changes throughout each transformation, making the transition even more obvious and difficult. When people come to me for advice about managing MS through lifestyle changes, I feel like an imposter. Yes, for almost two years I was eating strictly healthy and following all the health trends. But now, I don't really think about them. I feel inauthentic talking to people about what they should do to be healthier because I don't currently follow those practices. Sometimes, I wish I could recapture that energy, passion, discipline, and motivation I had to be so healthy. But I'm not perfect, and I am certainly not the perfect patient. For now, I will enjoy my indulgences. I will remind myself that nothing in life is permanent and that life has many chapters. I will never be the perfect patient, because there is no perfect patient. It is not my fault I have MS, and there is no need to punish myself more for it. I'm sure my healthy habits will come back to me one day. For now, I will enjoy myself in ways I never even thought possible a few years ago. And I'll try to let go of the guilt that comes from not living up to an impossible standard. Maybe the healthiest thing I can do is accept myself exactly as I am today, and try my best to live in the present.
Yahoo
an hour ago
- Yahoo
SINTX Technologies Announces Strategic Vision Focused on Expansion Across Key Sectors
New leadership and recapitalization to accelerate commercialization of proprietary silicon nitride technologies in medical and high-growth markets SALT LAKE CITY, Utah, June 12, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ('SINTX' or the 'Company'), the only FDA-registered producer of implantable silicon nitride and a global leader in advanced ceramics, today announced a renewed corporate vision and strategic plan to accelerate commercialization and unlock the full value of its intellectual property portfolio. This follows the company's successful recapitalization in February 2025 and the restructure of its leadership team and Board of Directors. A Legacy of Innovation in Silicon Nitride In 2008 SINTX Technologies made history with the first FDA-cleared implant material that is neither metal nor plastic—but medical-grade silicon nitride. The initial clearance covered a family of interbody devices and marked a pivotal moment in spinal surgery. These implants offered a unique trifecta of benefits: antimicrobial activity, osteogenic potential, and radiographic translucency. With over 50,000 spinal implants successfully placed worldwide, SINTX has demonstrated the clinical viability and long-term advantages of this revolutionary biomaterial. Today, SINTX remains the industry leader in silicon nitride technology, with 18 issued U.S. patents and 84 pending applications. Known for its strength, biocompatibility, and infection-resistant properties, the company's proprietary ceramic platform has applications across multiple markets—including the $62 billion global orthopedic implant sector, as well as emerging fields like agribiotech and performance textiles. Renewed Vision and Mission SINTX is now taking this one step further by developing next-generation hybrid biomaterials that combine the biological performance of silicon nitride and merging the flexibility, and manufacturability of polymers like PEEK and PEKK. These new composites are being optimized for applications in spine, oral/maxillofacial (OMF), cranio-maxillofacial (CMF), and oncologic reconstruction. 'Our mission is clear: to drive sustainable growth and value creation by collaborating with market leaders who recognize the transformative potential of silicon nitride,' said Mr. Eric Olson, CEO of SINTX Technologies. 'With a strengthened balance sheet and a robust intellectual property portfolio, we are uniquely positioned to accelerate commercialization and deliver superior outcomes for patients, customers, and shareholders alike.' Strategic Initiatives and Market Expansion SINTX is actively pursuing strategic partnerships and licensing opportunities to expand the reach of its technology. The company's near-term focus includes: Joint Ventures: Collaborating with established manufacturers in orthopedics, wound care, agribiotech, and other potential sectors to integrate silicon nitride into next-generation products. IP Monetization: Unlocking value from its extensive patent portfolio through licensing agreements and technology transfer initiatives. Operational Excellence: Enhancing AI supported 3D manufacturing capabilities at its FDA cleared and ISO certified headquarters to support anticipated growth and ensure the highest quality standards. Commitment to Stakeholders As SINTX enters this new era, the Company reaffirms its commitment to transparency, disciplined execution, and long-term value creation for all stakeholders. 'We are grateful for the continued support of our shareholders and partners,' said Mr. Olson. 'Together, we will realize the full potential of silicon nitride and secure SINTX's position as a leader in advanced ceramics. For more information, please visit About SINTX Technologies, Inc. Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter new markets. For more information on SINTX Technologies or its materials platform, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ('PSLRA') that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,' "future," "likely," "may," "should," "will" and similar references to future periods. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. Forward looking statements include our efforts to develop next-generation hybrid biomaterials, our expectation that will drive sustainable growth and value creation, and that we will expand the reach of our technology pursuing strategic partnerships and licensing opportunities. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in developing and commercializing medical device technologies. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 19, 2025, and in SINTX's other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law. Business and Media Inquiries for SINTX:SINTX Technologies, Inc. 801.839.3502IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
